ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037

Chicago, IL (UroToday.com) Dr. Lara and colleagues presented their preliminary results from the ECHO-202/KEYNOTE-037 study assessing epacadostat + pembrolizumab among patients with advanced renal cell carcinoma (RCC) at today’s 2017 ASCO Annual meeting genitourinary cancer poster session. Epacadostat is an oral inhibitor of indoleamine 2,3-dioxygenase 1, which is a tryptophan-catabolizing enzyme that induces immune tolerance by T-cell suppression. Initial data suggest that epacadostat has antitumor activity when combined with checkpoint inhibitors, including the PD-1 inhibitor pembrolizumab.

ECHO-202/KEYNOTE-037 is an ongoing open-label, phase I/II study evaluating epacadostat + pembrolizumab in multiple tumor types. For this analysis, eligible patients had (i) advanced clear-cell RCC, (ii) prior antiangiogenic therapy, and (iii) no prior checkpoint inhibitor therapy. In the phase I portion of the trial, patients received dose escalation epacadostat (25, 50, 100, or 300 mg PO BID) + pembrolizumab (2 mg/kg or 200 mg IV Q3W). For the phase II trial, 100 mg BID epacadostat + 200mg Q3W pembrolizumab was selected for treatment. Response rate was assessed using the RECIST 1.1 criteria and tolerability was assessed in patients receiving ≥1 epacadostat + pembrolizumab dose. There were 33 patients (phase I – n=11, phase II – n=22) enrolled in the trial, with a median age of 63 years, 70% of patients were male, and majority were Caucasian (97%). There were 6% of patients with favorable MSKCC criteria, 64% were intermediate, and 12% of patients were poor criteria. Among 30 patients with evaluable data, 63% had 0-1 and 37% had ≥2 prior therapies, respectively. Among patients with 0-1 prior therapies, the objective response rate (ORR) was 47% and disease control rate (DCR) was 58%. Among patients with ≥2 prior therapies, ORR was 0% and DCR was 36%. At the time of analysis, all patients demonstrating a treatment response were still ongoing (range: 1-372 days). Adverse events occurred in 10% of patients, including fatigue, rash, arthralgia, diarrhea, pruritus, and pyrexia.

In conclusion, epacadostat + pembrolizumab was generally well tolerated, with encouraging outcomes in these high-risk patients with failed prior therapy. Given the dismal outcomes for these patients with prior failed therapy, novel clinical trials demonstrating improved PFS and OS are desperately needed. A phase III trial is planned and we look forward to these results.
Clinical trial: NCT02178722

Presented By: Primo Lara, University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA

Co-Authors: Todd Michael Bauer, Omid Hamid, David C. Smith, Thomas Gajewski, Tara C. Gangadhar, Bradley G. Somer, Emmett V. Schmidt, Yufan Zhao, Hema Gowda, Anthony J. Olszanski

Written By: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre
Twitter: @zklaassen_md

at the 2017 ASCO Annual Meeting - June 2 - 6, 2017 – Chicago, Illinois, USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe